Precipio has launched its HemeScreen BCR-ABL 2.0 assay, a product that offers superior clinical coverage, workflow simplicity, and cost-effectiveness. The product is the only panel on the market that provides quantitative coverage of four clinically relevant breakpoints, improving patient care. It also includes an ABL1 mutation detection feature that eliminates the need for an additional testing step. The product comes with an automated analysis software that can be integrated into the laboratory's information system or the practice's electronic medical records system.